Cognitive · In Clinical Trials
Cortexin
No lawful US pathway
01 · Overview
Cortexin is a complex mixture of low-molecular-weight polypeptides extracted from animal cerebral cortex and used mainly in Russia and neighboring countries for neurological indications. It is not approved by the FDA.
In rats, Cortexin improved neurological recovery and antioxidant activity and reduced brain tissue necrosis in models of acute and chronic brain ischemia, and in vitro it bound AMPA, kainate, metabotropic glutamate, and GABA-A receptors, suggesting glutamatergic and GABAergic actions (PMID 34260655). In the same study, radiolabeled Cortexin crossed the blood-brain barrier in mice at concentrations of about 6 to 8 percent of blood levels (PMID 34260655).
02 · Research summary & key findings
Russian randomized studies have reported benefits, including dose-dependent improvement in neurological symptoms, asthenia, and sleep in 189 patients with chronic cerebral ischemia (PMID 30335070) and better cognitive and mood scores as add-on therapy in 110 patients with type 2 diabetes complications (PMID 42133422), though most compared against standard care rather than placebo. An independent systematic review found only one eligible Cortexin trial (80 participants) and rated the certainty of evidence for animal-derived nootropics as low to very low (PMID 36324709). The heterogeneous peptide composition complicates mechanistic validation and regulatory assessment.
03 · Regulatory status
Cortexin is currently undergoing clinical trials. It is not yet FDA-approved and is available only through clinical research settings or investigational protocols.
No lawful pathway today
Cortexin is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States, so we do not sell it and will not book a consultation for it. That can change: in 2026 FDA began reviewing several peptides for compounding. If you are working on the goal it is studied for, a licensed clinician can tell you what is lawfully available, which may be something else.
Tell me if the status changes
One email, only if this compound's regulatory standing actually moves. Not a newsletter, not a sales sequence.
Looking for a lawful, clinician-prescribed option for cognitive support?
Cortexin is still in clinical trials, is not FDA-approved, and has no lawful US compounding pathway, so we do not offer it and no clinician we work with will prescribe it. Products sold online as “research chemicals” are not made or tested to the standards required of medicines. If you are working on cognitive support, a licensed clinician can tell you at a free consultation whether an FDA-approved or lawfully compounded treatment fits you, or whether nothing does.
Explore lawful options (free intake)About 3 minutes. If a protocol is prescribed through our provider, we earn 10% of the sale. See the receipts.
04 · Administration routes
- Intramuscular injection
References
- [1][Dose-dependent effects of cortexin in chronic cerebral ischemia (results of a multicenter randomized controlled study)] Zh Nevrol Psikhiatr Im S S Korsakova, 2018. PMID 30335070
- [2]Neuroprotective action of Cortexin, Cerebrolysin and Actovegin in acute or chronic brain ischemia in rats PLoS One, 2021. PMID 34260655
- [3]The efficacy and safety of animal-derived nootropics in cognitive disorders: Systematic review and meta-analysis Cereb Circ Cogn Behav, 2021. PMID 36324709
- [4][Cortexin in the comprehensive treatment of neurological complications of type 2 diabetes mellitus. (Results of the DIACORT multicenter randomized clinical trial)] Zh Nevrol Psikhiatr Im S S Korsakova, 2026. PMID 42133422
Primary literature
- PubMed: "Cortexin"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "Cortexin"
Registered interventional and observational studies, including status and phase.
- PubChem: "Cortexin"
Chemical structure, molecular properties, and bioactivity data.
Related peptides in Cognitive
Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed. Clinicians: join the network.